Written by Michael Sassano, Founder and Interim CEO, SOMAÍ Prescription drugs
Most US hashish firms fascinated about Europe give attention to the fallacious quantity. They see €6/gram in Germany, £8 at a UK clinic, or AUD$10 in an Australian dispensary, run a fast foreign money conversion, and conclude the margin is a goldmine.
Let’s have a look at the details: it isn’t – not until you deeply perceive the channel.
Whether or not Europe works in your firm relies on three brutal questions:
- Do you’ve got extra capability? No surplus, no commerce case—construct a powerful margin EU vertical as an alternative.
- Are you vertically built-in at dwelling? If sure, the one mannequin that efficiently replicates your economics in Europe is proudly owning the vertical there too.
- Is your U.S. wholesale value materially under European importer costs? That is the one situation the place buying and selling alone is sensible, and even then, you’ll nonetheless want distribution infrastructure on the European facet.
There may be one huge constraint throughout all these markets: EU-GMP certification. No EU-GMP means completely no pharmacy entry in Germany, the UK, or Australia. Germany can be shifting towards blocking GACP-to-GMP conversions, so good operators ought to assume that window is quickly closing.
Germany: The Channel Squeeze
Germany is the most important open hashish market in Europe. As of July 2026, state insurance coverage not covers hashish flowers — self-pay is now the whole market.
- The Actuality: A US vendor receives at importer degree: €0.75–1.75/gram for greenhouse ($0.81–1.89), €1.75–3.75/gram for indoor ($1.89–4.05).
- The Patent Price: The affected person pays: €2.50–4.00/gram for greenhouse, €5.00–8.00/gram for indoor. The Bloomwell Hashish Barometer put the self-pay common at €4.52/gram in Q1 2026 — 60% of merchandise under €4.00/gram.
- The Leakage: Between importer and affected person: a distributor taking 15–25%, a pharmacy including 30–50% underneath the AMPreisV ordinance, clinics incomes 5–12% in advertising and marketing charges.
- The Backside Line: The channel takes 45–62% of retail. The vendor retains the remainder.
Germany: value stack from vendor to affected person (EUR/g). USD equal in bars.
United Kingdom: The Non-public Prescription Hurdle
The UK runs on non-public prescription routed via clinic networks to specialist pharmacies. There is no such thing as a insurance coverage; each buy is out-of-pocket.
- The Actuality: Importer costs: £0.90–2.00/gram greenhouse ($1.14–2.54), £2.00–3.25/gram indoor ($2.54–4.13).
- Affected person Price: Affected person retail for mainstream product: £6.50–8.00/gram, with a verified common of £6.95/gram in December 2025. Funds product runs £3.95–5.50/gram. High shelf reaches £10–13/gram — not the place the amount sits.
- The Leakage: Distributor taking 20% relying on clinic entry, a pharmacy is simply round 15%, whereas clinics can management 40-60% relying on distribution entry.
- The Backside Line: Distribution, clinic, and pharmacy mixed take 64–74% of what the affected person pays.
UK: value stack from vendor to affected person (GBP/g). USD equal in bars.
READ MORE…
Australia: Low Costs, Simple Entry
Australia pays the bottom wholesale costs of the three markets and has probably the most quick access pathway. TGA accepts nearly any nation certification. Most quantity runs via Authorised Prescribers. The market is dominated by vertically built-in operators.
- The Actuality: Importer costs: AUD$1.50–2.00/gram greenhouse ($0.98–1.30), AUD$2.50–4.00/gram indoor ($1.63–2.60).
- Affected person Price: Affected person retail: AUD$4.60–6.60/gram for greenhouse, AUD$8.00–12.00/gram for indoor mainstream. The ground has dropped to AUD$3.30/gram — 39% of SKUs now priced under AUD$10.
- The Leakage: Distributor margin runs 10–35% by quantity tier. Pharmacies cost a flat AUD$15–20 dishing out charge per bundle — concentrating on 20%. Clinics earn round 20-50% of wholesale through ESSA agreements.
- The Backside Line: The channel takes 54–69% of retail.
Australia: value stack from vendor to affected person (AUD/g). USD equal in bars.
The US Baseline
California out of doors growers at this time promote at $0.66–0.88/gram — under their all-in price of $0.92/gram. Cultivation, obligatory testing, and excise tax depart most promoting at a loss. Many are exiting. Greenhouse reaches $1.10–1.65/gram, indoor $1.65–2.20/gram.
Personal the dispensary and the image modifications. Greenhouse 1/8ths promote for $20–40 at retail ($5.71–11.43/gram). Indoor 1/8ths at $35–60 ($10.00–17.14/gram). The dispensary captures 45–55% gross margin. With out it, the grower captures 7–11% of shelf value.
Restricted-licence states present a unique mannequin. Ohio averages $6.59/gram retail. New Jersey and New York: $7–10/gram. Florida MSO medical: $8–12/gram. Florida operators are legally required to be vertically built-in — develop, course of, and promote. They seize the complete chain. Zero channel leakage.
What the Comparability Exhibits
The chart under converts all markets to USD. Two bars per section: what the vendor receives and what the affected person pays. The determine on the suitable is the proportion that stays within the channel.
All markets — vendor value vs. affected person retail in USD. FX approx. mid-2026: EUR $1.08 | GBP $1.27 | AUD $0.65. California retail = licensed dispensary pricing. Ohio and NJ/NY vendor = estimated wholesale.
EU and Australian retail in USD is decrease than California premium dispensary pricing. Ohio and NJ/NY retail ($6–10/gram) is broadly corresponding to Germany and UK retail in USD. The distinction will not be the retail value. The distinction is how a lot of the chain the operator owns.
Florida makes the purpose cleanly: 0% to the channel. The operator is the channel.
Buying and selling or Constructing – The Proper Query
There are two operator sorts and two totally different solutions.
In case you are a big California out of doors grower drowning under price, buying and selling into Europe is a lifeline. EU greenhouse importer costs are corresponding to or higher than the house market in USD phrases, and your home various is structural decline.
Nevertheless, in case you are a limited-license indoor operator already incomes $7–12/gram with a dispensary, promoting to a European distributor for $2.97 (USD) is a large step backwards. You’re taking on GMP certification, new regulatory burdens, and foreign money publicity for a fraction of your home margin. For you, buying and selling doesn’t work.
Constructing a Vertical in Europe
Totally vertical European operators considerably outperform U.S. multi-state operators, since EU hashish firms with vertical built-in entry command pharmaceutical-grade EBITDA margins (sometimes 30–50%) and bigger valuation multiples. Moreover:
- There is no such thing as a 280E.
- There are not any particular state assessed develop taxes.
- There are not any banking restrictions.
- There are not any state-by-state licensing partitions to limit economies of scale.
A single EU-GMP facility can service Germany, the UK, Australia, and rising markets from one infrastructure base. That working leverage doesn’t exist within the U.S. mannequin.
U.S. MSOs are constructed on regulatory arbitrage inside state borders. European verticals are constructed on pharmaceutical infrastructure that’s genuinely onerous to copy. That’s the moat, and that’s the a number of.
Buying and selling in Europe is a short-term arbitrage play. Constructing in Europe is a enterprise. The margin stays within the channel until you personal it.
Sources: *interviews; California DCC dashboard (Nov 2025); StratCann / GCX Fall 2025 International Hashish Report; Leven Therapeutics Q2 2025 investor disclosure; Bloomwell Hashish Barometer Q1 2026; Medbud.wiki Dec 2025; Cannabiz / honahlee 2025; BusinessOfCannabis.com (Jul 2026 GKV ban); CDTFA AMP benchmark; Hashish Enterprise Occasions / Ohio CRA 2025. FX charges approximate mid-2026.
